Patiromer sorbitex calcium is under clinical development by Vifor Pharma Management and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Patiromer sorbitex calcium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Patiromer sorbitex calcium overview
Patiromer sorbitex calcium (RLY5016, Veltassa) is a cross-linked polymer of calcium. It is formulated as powder for suspension for oral route of administration. Veltassa is indicated for treatment of hyperkalemia in adult patients with chronic kidney disease and and hyperkalemia. It is developed through use of its proprietary polymer platform, also indicated for treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.
It is also under development for hyperkalemia and chronic kidney disease.
It was also under development for the treatment of resistant hypertension in patients with chronic kidney disease.
Vifor Pharma Management overview
Vifor Pharma Management, a subsidiary of CSL Ltd, focuses on the discovery, development, and marketing of prescription medicines and non-prescription drugs specializes in areas such as iron deficiency, nephrology, and cardio-renal therapies. The company is headquartered in Glattbrugg, Switzerland.
For a complete picture of Patiromer sorbitex calcium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
